Analysis of the gene expression data was performed using the multivariate methods hierarchical clustering and principal component analysis (PCA). The cut off value was set as 30 Cq. Missing data of duplicates were filled by interpolation. Data not obtained by amplification were filled by maximum Cq value of the tested gene plus 0.5. We were not able to find genes with invariable expression that would be suitable for normalization. The data were normalized to the global expression of all genes and consequnetly, gene expression levels are relative to the other genes in the panel. For multivariate analysis the data were also autoscaled to give the genes the same clustering weights.
Purpose of the Study

Patients and Methods
References
To assess the molecular profiles of circulating tumor cells (CTCs) from breast cancer (BC) patients (early and metastatic) and to evaluate their potential as prognostic and therapy indicators.
Patients: A total of 137 patients with diagnosed BC at stages I to III and 60 metastatic patients were enrolled into a prospective study between 2008 -2010. Peripheral blood (5ml) for CTC-detection was collected before chemotherapy (early BC) and before starting a new line of treatment (metastatic BC). The AdnaTest BreastCancer CTC enrichment and detection from the peripheral blood were performed using AdnaTest BreastCancer TM (AdnaGen AG, Germany). The detection of CTCs via analysis of tumorassociated mRNA was performed in a multiplex PCR for the 3 transcripts: HER2, MUC1 and GA733-2. Gene specific preamplification (GSPA): cDNA samples established with the AdnaTest were profiled for 31 markers on a microfluidic BioMark HD System using 48x48 DynamicArray integrated fluidic circuits (Fluidigm, USA). GSPA was carried out in TaqMan PreAmp Master Mix according to manufacturer protocol using in house designed assays in final concentration of 25nM. Biomark Gene Expression Data Analysis and Melt Curve Analysis software were used to obtain Cq-values and Tm. qPCR-results have been analyzed by GENEX v.s. 5.0 software (MultiD, SE).
Gene Expression Analysis for Metastatic Breast Cancer
CTCs were found in 42% of the metastatic and in 26% of the early BC patients. There is a difference between gene expression profiles of the CTCs within the metastatic process. The mRNA levels of the markers used in routine for CTC identification (GA7332, MUC1, KRT19) change with the progression of the disease.
We conclude that CTCs enriched by the AdnaGen-technology are heterogeneous and do not necessarily express EPCAM. Even CTCs with low EPCAM expression but with elevated KRT19 and AURKA levels may represent a subgroup of high risk metastatic BC patients.
In early BC, after comparison of the CTC-positive and negative samples, we may conclude, that the biggest differences were found for EPCAM, KRT19, WHSC1L1, AURKA and TOP2A.
The predictive value of expression profiles in CTCs for the therapeutic interventions will be further prospectively evaluated. Cluster analysis of early BC-CTC expression data enabled to identify several discriminating genes as EPCAM, WHSC1L1, PARP, KRT19, TOP2A, AURKA when comparing the positive and negative CTC-samples.
In contrast to expression profiles obtained in MBC, we can not definitively divide the CTC positive and CTC negative samples of the early BC patients. The biggest differences were found for EPCAM, KRT19, WHSC1L1, AURKA and TOP2A.
